Evidence map›Paper›PMID 34841014›Full record

ArticleBone reports2021

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients.

A Beltran-Bless, M Murshed, M Zakikhani, I Kuchuk, N Bouganim, S Robertson, N Kekre, L Vandermeer, J Li, C L Addison and 3 more

Open access · goldAbstract read
In one paragraph

Article in Bone reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

A Beltran-BlessDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, Canada.
M MurshedDepartment of Medicine, Faculty of Dentistry, Shriners Hospital for Children, McGill University, Montreal, Canada.
M ZakikhaniDepartment of Medicine, Research Institute of the McGill University Health Center, Montreal, Canada.
I KuchukDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, Canada.
N BouganimDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, Canada.
S RobertsonDepartment of Pathology, The Ottawa Hospital and the University of Ottawa, Ottawa, Canada.
N KekreDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, Canada.
L VandermeerDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, Canada.
J LiDepartment of Medicine, Research Institute of the McGill University Health Center, Montreal, Canada.
C L AddisonCentre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada.
F RauchDepartment of Pediatric Surgery, McGill University Health Center, Montreal, Canada.
M ClemonsDivision of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, Canada.
R KremerDepartment of Medicine, Research Institute of the McGill University Health Center, Montreal, Canada.
McGill University Health Centre · CAOttawa Hospital · CAOttawa Hospital Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite widespread use of repeated doses of potent bone-targeting agents (BTA) in oncology patients, relatively little is known about their in vivo effects on bone homeostasis, bone quality, and bone architecture. Traditionally bone quality has been assessed using a trans-iliac bone biopsy with a 7 mm "Bordier" core needle. We examined the feasibility of using a 2 mm "Jamshidi™" core needle as a more practical and less invasive technique.

methodsPatients with metastatic breast cancer on BTAs were divided according to the extent of bone metastases. They were given 2 courses of tetracycline labeling and then underwent a posterior trans-iliac trephine biopsy and bone marrow aspirate. Samples were analyzed for the extent of tumor invasion and parameters of bone turnover and bone formation by histomorphometry.

resultsTwelve patients were accrued, 1 had no bone metastases, 3 had limited bone metastases (LSM) (<3 lesions) and 7 had extensive bone metastases (ESM) (>3 lesions). Most of the primary tumors were estrogen receptor (ER)/progesterone receptor (PR) positive. The procedure was well tolerated. The sample quality was sufficient to analyze bone trabecular structure and bone turnover by histomorphometry in 11 out of 12 patients. There was a good correlation between imaging data and morphometric analysis of tumor invasion. Patients with no evidence or minimal bone metastases had no evidence of tumor invasion. Most had suppressed bone turnover and no detectable bone formation when treated with BTA. In contrast, 6 out of 7 patients with extensive bone invasion by imaging and evidence of tumor cells in the marrow had intense osteoclastic activity as measured by the number of osteoclasts. Of these 7 patients with ESM, 6 were treated with BTA with 5 showing resistance to BTA as demonstrated by the high number of osteoclasts present. 3 of these 6 patients had active bone formation. Based on osteoblast activity and bone formation, 3 out of 6 patients with ESM responded to BTA compared to all 3 with LSM. Compared to untreated patients, all patients treated with BTA showed a trend towards suppression of bone formation, as measured by tetracycline labelling. There was also a trend towards a significant difference between ESM and LSM treated with BTA, highly suggestive of resistance although limited by the small sample size. DISCUSSION: Our results indicate that trans-iliac bone biopsy using a 2 mm trephine shows excellent correlation between imaging assessment of tumor invasion and tumor burden by morphometric analysis of bone tissues. In addition, our approach provides additional mechanistic information on therapeutic response to BTA supporting the current clinical understanding that the majority of patients with extensive bone involvement eventually fail to suppress bone turnover (Petrut B, et al. 2008). This suggests that antiresorptive therapies become less effective as disease progresses.

Indexed as

astasis AI, Aromatase inhibitorsBM, Bone metBone biopsyBone microarchitectureBone-targeted agentsBone turnoverBPs, BisphosphonatesBreast cancerBTAs, Bone targeting agentsCK, Cytokeratin stainingCM, Collagen materialDEXA, Dual-energy X-ray absorptiometryER, Estrogen receptorESM, Extensive skeletal metastasesHE, Haematoxylin and EosinHER2, Human Epidermal growth factor Receptor 2HistomorphometryIDC, Invasive ductal carcinomaIHC, Immunohistochemistry stainingLSM, Limited skeletal metastasesMB, Mineralized boneOB, OsteoblastsOC, OsteoclastsOS, Osteoid surfacePAM, PamidronatePFA/PBS, Paraformaldehyde/phosphate buffer solutionPR, Progesterone receptorQCT, Quantitative CTSREs, Skeletal related eventsTRAP, Tartrate-resistant acid phosphatase stainingVKVG, von Kossa and van GiesonZol, Zoledronic acid

Identifiers

PMID34841014
PMCPMC8605385
OpenAlexW3209007010

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.